GlaxoSmithKline (NYSE: GSK) is increasing the amount of medicine it donates annually to fight intestinal worms among children in Africa.

GSK will increase production of the drug albendazole in India and South Africa in order to meet the commitment of 1 billion pills per year. The company, which operates its U.S. headquarters in Research Triangle Park, had previously committed 600,000 pills.

The expanded commitment, which is for five years, was announced at a World Health Organization conference about neglected tropical diseases.

"This pledge extends a long-term collaboration between WHO and GSK in tackling diseases that are perpetuated by poverty and keep people in poverty, especially in Africa,” said WHO Director General Dr. Margaret Chan.

According to GSK, the worms affect some 300 million people in Africa and 1.2 billion worldwide.

For more details about the announcement,

Get the latest news alerts: at Twitter.